Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2013

Open Access 01-12-2013 | PRECLINICAL STUDIES

Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition

Authors: Cheree Fitzgibbon, Saleh Ihmaid, Jasim Al-Rawi, Terri Meehan-Andrews, Christopher Bradley

Published in: Investigational New Drugs | Issue 6/2013

Login to get access

Summary

The benzoaxines have been developed from structurally similar chromones as specific inhibitors of the PI3K family to sensitize cancer cells to the effects of chemotherapeutic agents; most have been shown to do this through specific inhibition of DNA-PK and DNA repair mechanisms. In this study we examined the benzoxazine, 2-((3-methoxybut-3en-2-yl)amino)-8methyl-4H-benzo[1,3]oxazin-4one (LTUSI54). This compound had no DNA-PK or PI3K inhibitory activity but still sensitized HeLa cells to the effects of Etoposide. LTUSI54 works synergistically with Etoposide to inhibit growth of HeLa cells and sub G1 analysis indicates that this is not due to an increase in apoptosis. LTUSI54 neither enhances DSB formation due to Etoposide nor does it delay the repair of such damage. Cell cycle analysis shows a clear G2 block with Etoposide alone while, in combination with LTUSI54 there is an additional S phase arrest. Phospho-kinase analysis indicated that LTUSI54 engages key regulators of cell cycle progression, specifically p38α, p53 and ERK 1/2. From our results we hypothesize that LTUSI54 is promoting the cell cycle arrest through activation of p38α pathways, independent of p53 mechanisms. This results in a decrease in p53 phosphorylation and hence, restricted apoptosis. Changes in cell number appear to be the result of p38α pathways disrupting cell cycle progression, at the S and G2 checkpoints. Further investigation into the finer mechanisms by which LTUSI54 effects cell cycle progression would be of great interest in assessing this compound as a chemosensitising agent.
Literature
1.
Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA (1998) Etoposide targets topoisomerase IIa and IIb in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 53:78–85
2.
Wilmore E, Sd C, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW (2004) A novel DNA-dependent protein kinase inhibitoe, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103(12):4659–4665CrossRef
3.
Tanaka THH, Traganos F, Seiter K, Darzynkiewicz Z (2007) Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide. Relation to cell cycle phase. Cell Cycle 6(3):6CrossRef
4.
Karlsson-Rosenthal C, Millar JBA (2006) Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 16(6):285–292CrossRefPubMed
5.
Gabrielli B, Brooks K, Pavey S (2012) Defective cell cycle checkpoints as targets for anti-cancer therapies. Front Pharmacol 3
6.
Alexander BM, Pinnell N, Wen PY, D’Anrea A (2012) Targeting DNA repair and the cell cycle in gliolastoma. J Neuron Oncolocy 107:463–477CrossRef
7.
Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3(4):513–519PubMed
8.
Kung G, Konstantinidis K, Kitsis RN (2011) Programed necrosis, not apoptosis, in the heart. Circ Res 108:1017–1036CrossRefPubMed
9.
Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear K, Slade A, Thommes P, Martin NM, Newell DR, Smith GC, Curtin NJ (2012) Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Mol Cancer Ther 11(8):1789–1798PubMedCentralCrossRefPubMed
10.
Griffin RJ, Fontana G, Golding BT, Guiard S, Hardcastle IR, Leahy JJJ, Martin N, Richardson C, Rigoreau L, Stockley M, Smith GCM (2005) Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. J Med Chem 48:569–585CrossRefPubMed
11.
Ding J, Miao Z-H, Meng L-H, Geng M-Y (2006) Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci 27(6):338–344CrossRefPubMed
12.
Martin SA, Lord CJ, Ashworth A (2008) DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 18(1):80–86CrossRefPubMed
13.
Sánchez-Pérez I (2006) DNA repair inhibitors in cancer treatment. Clin Transl Oncol 8(9):642–646CrossRefPubMed
14.
Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW (2003) Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly (ADP-ribose) polymerase-1. Can Res 63(18):6008–6015
15.
Hosoya N, Miyagawa K (2009) Clinical importance of DNA repair inhibitors in cancer therapy. Memo 2(1):9–14CrossRef
16.
Workman P, Clarke PA, Raynaud FI, van Montfort RL (2010) Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Can Res 70(6):2146–2157CrossRef
17.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307(5712):1098–1101CrossRefPubMed
18.
Chiosis G, Rosen N, Sepp-Lorenzino L (2001) LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett 11(7):909–913CrossRefPubMed
19.
Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL, Zempolich KA (2006) Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cancer cell lines. Clin Cancer Res 12(1):250–256CrossRefPubMed
20.
Freshney RI (1992) Animal cell culture: a practical approach. IRL Press at Oxford University Press
21.
MacPhail SH, Banath JP, Yu TY, Chu EHM, Lambur H, Olive PL (2003) Expression of phosphorylated histone H2AX in culture cell lines following exposure to X-rays. Int J Radiat Biol 79(5):351–358CrossRefPubMed
22.
Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1(3):1458–1461CrossRefPubMed
23.
Ihmaid S, Al-Rawi J, Bradley C, Angove MJ, Robertson MN, Clark RL (2011) Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines. Bioorg Med Chem 19(13):3983–3994CrossRefPubMed
24.
Ihmaid SK, Al-Rawi JMA, Bradley CJ, Angove MJ, Robertson MN (2012) Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines. Eur J Med Chem 57:85–101CrossRefPubMed
25.
Clapham KM, Bardos J, Finlay MRV, Golding BT, Griffen EJ, Griffin RJ, Hardcastle IR, Menear KA, Ting A, Turner P (2011) DNA-dependent protein kinase (DNA-PK) inhibitors: structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain. Bioorg Med Chem Lett 21(3):966–970CrossRefPubMed
26.
Lock RB, Stribinskiene L (1996) Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56:4006–4012PubMed
27.
Kao J, Lavaf A, Lan C-H, Fu S (2010) Inhibition of γ-H2AX after ionizing radiation as a biological surrogate of impaired upstream DNA damage signaling and radiosensitivity. J Cancer Mol 5(2):49–54
28.
Banáth JP, Olive PL (2003) Expression of phosphorylated histone H2AX as a surrogate of call killing by drugs that create DNA double-strand breaks. Cancer Res 63:4347–4350PubMed
29.
Celeste A, Fernandez-Capetillo O, Kruhlak MJ, Pilch DR, Staudt DW, Lee A, Bonner RF, Bonner WM, Nussenzweig A (2003) Histone H2AX phosphyrlation is dispensable for the inital recognition of DNA breaks. Nat Cell Biol 5(7):675–679CrossRefPubMed
30.
Collins I, Garrett MD (2005) Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 5(4):366–373CrossRefPubMed
31.
de Klein A, Muijtjens M, van Os R, Verhoeven Y, Smit B, Carr AM, Lehmann AR, Hoeijmakers JHJ (2000) Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol 10(8):479–482CrossRefPubMed
32.
Yves P (2004) Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anti Cancer Agents 4(5):429–434CrossRef
33.
Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23(36):9408–9421CrossRefPubMed
34.
35.
Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108(2):153–164CrossRefPubMed
36.
Shieh S-Y, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91(3):325–334CrossRefPubMed
37.
Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281(5383):1674–1677CrossRefPubMed
38.
39.
40.
Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11(2):175–189PubMedCentralCrossRefPubMed
41.
Skorski T (2007) DNA damage-dependent apoptosis. In: Srivastava R (ed) Apoptosis, cell signaling, and human diseases. Humana Press, pp 263–272
42.
43.
Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AEH, Yaffe MB (2005) MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 17(1):37–48CrossRefPubMed
44.
45.
46.
Dolado I, Nebreda AR (2008) Regulation of tumorigenesis by p38α MAP kinase. Stress Activated Protein Kinases Top Curr Genet 20:99–128CrossRef
47.
Mikhailov A, Patel D, McCance DJ, Rieder CL (2007) The G2 p38-mediated stress-activated checkpoint pathway becomes attenuated in transformed cells. Curr Biol 17(24):2162–2168PubMedCentralCrossRefPubMed
48.
Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Vousden KH (2005) HDM2 phosphorylation by MAPKAP kinase 2. Oncogene 24(12):1965–1972CrossRefPubMed
49.
Mebratu Y, Tesfaigzi Y (2009) How ERK1/2 activation controls cell proliferation and cell death is subcellular localization the answer? Cell Cycle 8(8):1168–1175PubMedCentralCrossRefPubMed
50.
Meloche S, Pouyssegur J (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 26(22):3227–3239CrossRefPubMed
51.
Balmanno K, Cook S (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16(3):368–377CrossRefPubMed
Metadata
Title
Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition
Authors
Cheree Fitzgibbon
Saleh Ihmaid
Jasim Al-Rawi
Terri Meehan-Andrews
Christopher Bradley
Publication date
01-12-2013
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-013-0031-z

Other articles of this Issue 6/2013

Investigational New Drugs 6/2013 Go to the issue

PHASE I STUDIES

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

PHASE I STUDIES

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

SHORT REPORT

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)

PHASE II STUDIES

A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

PRECLINICAL STUDIES

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation

PRECLINICAL STUDIES

ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits